CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

1. Longitudinal trends in community-onset bacteraemia caused by ceftriaxone non-susceptibleJAC-antimicrobial resistance · 2026
   Article
2. Prevalence and molecular characterization of multi-drug and extreme drug resistant Escherichia coli in companion animals in Bangladesh.Scientific reports · 2025
   Article
3. Efficacy of noncarbapenem therapy for the treatment of ceftriaxone-resistant Enterobacterales outside the urinary tract.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024
   Article
4. Prevalence and clinical significance of the genotypic carriage among ESBL phenotype-negativeFrontiers in cellular and infection microbiology · 2024
   Article
5. #AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance.JAC-antimicrobial resistance · 2023
   Review
6. Genetic Predictive Factors for Nonsusceptible Phenotypes and Multidrug Resistance in Expanded-Spectrum Cephalosporin-Resistant Uropathogenic Escherichia coli from a Multicenter Cohort: Insights into the Phenotypic and Genetic Basis of Coresistance.mSphere · 2022
   Article
7. A Proposal for a Classification Guiding the Selection of Appropriate Antibiotic Therapy for Intra-Abdominal Infections.Antibiotics (Basel, Switzerland) · 2022
   Review
8. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
9. Effective Antimicrobial Solutions for Eradicating Multi-Resistant and β-Lactamase-Producing Nosocomial Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2021
   Article
10. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.JAC-antimicrobial resistance · 2021
    Review
11. Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate.JAC-antimicrobial resistance · 2021
    Review

Corrections and comments

• Comment on
  PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress.2021

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract